Bladder Cancer in Older Adults

  • N. Talji
  • N. MottetEmail author
Living reference work entry


Bladder cancer (BC) is a disease of the elderly. Considering the increasing aging of the population, BC will become a more important public health challenge to manage in a very close future. However, the current treatment of BC in the elderly remains controversial. The purpose of this article is to review the previous literature to summarize and gather the current knowledge in order to describe the management and treatment of BC in the elderly, in all its aspects. Original articles in English as well as reviews and editorials were selected based on their clinical relevance. The definition of elderly can differ as it is based on varying chronological ages. However, it is commonly found in most BC literature reviews that the elderly may be affected more severely than the younger people. Even if the management of non-muscle-invasive BC (NMIBC) does not strongly differ from younger patients, the impact of adjuvant intravesical immunotherapy might be inferior. Patients with muscle-invasive BC (MIBC) may benefit from a multidisciplinary geriatric evaluation. Radical cystectomy (RC) remains the curative treatment to BC, and elderly patients should not be withheld a potentially lifesaving intervention only based on chronological age. Bladder-sparing techniques may be a potential replacing treatment approach for unsuitable patients to a major surgical approach. Geriatric assessment could help identify the frail elderly and customize their perioperative care. In conclusion the treatment of BC in the elderly has to be patient-centered and focused on biological age and functional reserves. Age per se should not be the key driver.


Bladder cancer Elderly Geriatrics assessment Treatment 


  1. Aldousari S, Kassouf W. Update on the management of non-muscle invasive bladder cancer. Can Urol Assoc J. 2010;4(1):56–64.PubMedPubMedCentralCrossRefGoogle Scholar
  2. Apolo AB, Hoffman V, Kaag MG, Latini DM, Lee CT, Rosenberg JE, Knowles M, Theodorescu D, Czerniak BA, Efstathiou JA. Summary of the 8th annual bladder cancer think tank: collaborating to move research forward. Urol Oncol. 2015;33:53–64. ElsevierPubMedCrossRefGoogle Scholar
  3. Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M. EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71(3):447–61.PubMedCrossRefGoogle Scholar
  4. Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, Herr H, Higgins G, Boyle MG. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17(10):3173–81.PubMedCrossRefGoogle Scholar
  5. Balducci L, Extermann M. Management of the frail person with advanced cancer. Crit Rev Oncol Hematol. 2000a;33(2):143–8.PubMedCrossRefGoogle Scholar
  6. Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000b;5(3):224–37.PubMedCrossRefGoogle Scholar
  7. Bellmunt J, Fougeray R, Rosenberg J, Von der Maase H, Schutz F, Salhi Y, Culine S, Choueiri T. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol. 2013;24(6):1466–72.PubMedCrossRefGoogle Scholar
  8. Bellmunt J, Orsola A, Leow J, Wiegel T, De Santis M, Horwich A. Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25:iii40. mdu223PubMedCrossRefGoogle Scholar
  9. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee J-L, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26.PubMedPubMedCentralCrossRefGoogle Scholar
  10. Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the “Silver Tsunami”: prevalence trajectories and comorbidity burden among older cancer survivors in the United States. In: AACR; 2016.CrossRefGoogle Scholar
  11. Botteman M, Pashos C, Hauser R, Laskin B, Redaelli A. Quality of life aspects of bladder cancer: a review of the literature. Qual Life Res. 2003;12(6):675–88.PubMedCrossRefGoogle Scholar
  12. Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. Chichester: Wiley-Blackwell; 2016. ISBN: 978-1-119-26357-9.Google Scholar
  13. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234–41.PubMedCrossRefGoogle Scholar
  14. Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, Kirkels WJ, Da Silva FC, Oosterlinck W, Prescott S. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non–muscle-invasive stage Ta–T1 urothelial bladder cancer patients treated with 1–3 years of maintenance bacillus Calmette-Guérin. Eur Urol. 2016;69(1):60–9.PubMedCrossRefGoogle Scholar
  15. Capitanio U, Isbarn H, Shariat SF, Jeldres C, Zini L, Saad F, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysist. Urology. 2009;74(4):858–64.PubMedCrossRefGoogle Scholar
  16. Cho KS, Hwang T-K, Kim BW, Yoon DK, Chang S-G, Kim SJ, Park JY, Cheon J, Sung GT, Hong SJ. Differences in tumor characteristics and prognosis in newly diagnosed Ta, T1 urothelial carcinoma of bladder according to patient age. Urology. 2009;73(4):828–32. e821PubMedCrossRefGoogle Scholar
  17. Crome P, Lally F, Cherubini A, Oristrell J, Beswick AD, Clarfield AM, Hertogh C, Lesauskaite V, Prada GI, Szczerbińska K. Exclusion of older people from clinical trials. Drugs Aging. 2011;28(8):667–77.PubMedCrossRefGoogle Scholar
  18. Dash A, Galsky MD, Vickers AJ, Serio AM, Koppie TM, Dalbagni G, Bochner BH. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006;107(3):506–13.PubMedCrossRefGoogle Scholar
  19. De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Gil T, Marreaud S, Daugaard G, Skoneczna I. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2011;30(2):191–9.PubMedPubMedCentralCrossRefGoogle Scholar
  20. De Santis M, Wiechno P, Lucas C, Lin C, Su W, Bellmunt J, Legrand K, Fougeray R, Culine S. 812PDMATURE survival (OS) data of a randomised international phase II trial (JASINT1): vinflunine (VFL)-gemcitabine (GEM) vs. VFL-CBDCA in CDDP-unfit patients (PTS) with advanced Urothelial Carcinoma (UC). Ann Oncol. 2014;25(suppl 4):iv282.CrossRefGoogle Scholar
  21. Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM, Sandler HM. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol. 2009;27(25):4055–61.PubMedPubMedCentralCrossRefGoogle Scholar
  22. Epstein JI, Amin MB, Reuter VR, Mostofi FK, Bladder Consensus Conference Committee. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol. 1998;22(12):1435–48.PubMedCrossRefGoogle Scholar
  23. Fedeli U, Fedewa SA, Ward EM. Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J Urol. 2011;185(1):72–8.PubMedCrossRefGoogle Scholar
  24. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.PubMedCrossRefGoogle Scholar
  25. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, Dandona L. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2016;388:1603–58.Google Scholar
  26. Fonteyne V, Ost P, Bellmunt J, Droz JP, Mongiat-Artus P, Inman B, Paillaud E, Saad F, Ploussard G. Curative treatment for muscle invasive bladder cancer in elderly patients: a systematic review. Eur Urol. 2018;73:40–50.PubMedCrossRefGoogle Scholar
  27. Froehner M, Brausi MA, Herr HW, Muto G, Studer UE. Complications following radical cystectomy for bladder cancer in the elderly. Eur Urol. 2009;56(3):443–54.PubMedCrossRefGoogle Scholar
  28. Fung C, Pandya C, Guancial E, Noyes K, Sahasrabudhe DM, Messing EM, Mohile SG. Impact of bladder cancer on health related quality of life in 1,476 older Americans: a cross-sectional study. J Urol. 2014;192(3):690–5.PubMedPubMedCentralCrossRefGoogle Scholar
  29. Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg CN, Bajorin DF. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. J Clin Oncol. 2011;29(17):2432–8.PubMedCrossRefGoogle Scholar
  30. Gilbert SM, Wood DP, Dunn RL, Weizer AZ, Lee CT, Montie JE, Wei JT. Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI). Cancer. 2007;109(9):1756–62.PubMedCrossRefGoogle Scholar
  31. Gill TM, Baker DI, Gottschalk M, Gahbauer EA, Charpentier PA, de Regt PT, Wallace SJ. A prehabilitation program for physically frail community-living older persons. Arch Phys Med Rehabil. 2003;84(3):394–404.PubMedCrossRefGoogle Scholar
  32. Goossens-Laan CA, Leliveld AM, Verhoeven RH, Kil PJ, Bock GH, Hulshof MC, Jong IJ, Coebergh JWW. Effects of age and comorbidity on treatment and survival of patients with muscle-invasive bladder cancer. Int J Cancer. 2014;135(4):905–12.PubMedCrossRefGoogle Scholar
  33. Gore JL, Litwin MS, Lai J, Yano EM, Madison R, Setodji C, Adams JL, Saigal CS, Project UDiA. Use of radical cystectomy for patients with invasive bladder cancer. J Natl Cancer Inst. 2010;102:802.PubMedPubMedCentralCrossRefGoogle Scholar
  34. Gupta A, Atoria CL, Ehdaie B, Shariat SF, Rabbani F, Herr HW, Bochner BH, Elkin EB. Risk of fracture after radical cystectomy and urinary diversion for bladder cancer. J Clin Oncol. 2014;32(29):3291–8.PubMedPubMedCentralCrossRefGoogle Scholar
  35. Hautmann RE, de Petriconi RC, Pfeiffer C, Volkmer BG. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol. 2012;61(5):1039–47.PubMedCrossRefGoogle Scholar
  36. Heiner JG, Terris MK. Effect of advanced age on the development of complications from intravesical bacillus Calmette-Guerin therapy. Urol Oncol. 2008;26:137–40. ElsevierPubMedCrossRefGoogle Scholar
  37. Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol. 1999;162(1):74–6.PubMedCrossRefGoogle Scholar
  38. Herr HW. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol. 2001;19(1):89–93.PubMedCrossRefGoogle Scholar
  39. Hewitt J, Moug SJ, Middleton M, Chakrabarti M, Stechman MJ, McCarthy K, Collaboration OPSO. Prevalence of frailty and its association with mortality in general surgery. Am J Surg. 2015;209(2):254–9.PubMedCrossRefGoogle Scholar
  40. Hofbauer SL, Shariat SF, Klatte T. Non-muscle-invasive bladder cancer in the elderly patient. Curr Geriatr Rep. 2014;3(1):42–7.CrossRefGoogle Scholar
  41. Hollenbeck BK, Miller DC, Taub D, Dunn RL, Underwood W, Montie JE, Wei JT. Aggressive treatment for bladder cancer is associated with improved overall survival among patients 80 years old or older. Urology. 2004;64(2):292–7.PubMedCrossRefGoogle Scholar
  42. Howlader N, Noone A, Krapcho M. SEER cancer statistics review, 1975–2013. 2013.
  43. Hurria A, Gupta S, Zauderer M, Zuckerman EL, Cohen HJ, Muss H, Rodin M, Panageas KS, Holland JC, Saltz L. Developing a cancer-specific geriatric assessment. Cancer. 2005;104(9):1998–2005.PubMedCrossRefGoogle Scholar
  44. Hurria A, Cohen HJ, Extermann M. Geriatric oncology research in the cooperative groups: a report of a SIOG special meeting. J Geriatr Oncol. 2010;1(1):40–4.PubMedPubMedCentralCrossRefGoogle Scholar
  45. Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtman SM, Gajra A, Bhatia S, Katheria V. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457–65.PubMedPubMedCentralCrossRefGoogle Scholar
  46. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341(27):2061–7.PubMedCrossRefGoogle Scholar
  47. James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, Crundwell M, Sizer B, Sreenivasan T, Hendron C. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477–88.PubMedCrossRefGoogle Scholar
  48. Joudi FN, Smith BJ, O’Donnell MA, Konety BR. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol. 2006;175(5):1634–40.PubMedCrossRefGoogle Scholar
  49. Kamat AM, Flaig TW, Grossman HB, Konety B, Lamm D, O’donnell MA, Uchio E, Efstathiou JA, Taylor JA III. Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat Rev Urol. 2015;12(4):225–35.PubMedCrossRefGoogle Scholar
  50. Karvinen KH, Courneya KS, North S, Venner P. Associations between exercise and quality of life in bladder cancer survivors: a population-based study. Cancer Epidemiol Prev Biomark. 2007;16(5):984–90.CrossRefGoogle Scholar
  51. Kassouf W, Swanson D, Kamat AM, Leibovici D, Siefker-Radtke A, Munsell MF, Grossman HB, Dinney CP. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the MD Anderson Cancer Center experience. J Urol. 2006;175(6):2058–62.PubMedCrossRefGoogle Scholar
  52. Ketelaars L, Pottel L, Lycke M, Goethals L, Ghekiere V, Santy L, Boterberg T, Van Den Noortgate N, Pottel H, Debruyne PR. Use of the Freund clock drawing test within the Mini-Cog as a screening tool for cognitive impairment in elderly patients with or without cancer. J Geriatr Oncol. 2013;4(2):174–82.PubMedCrossRefGoogle Scholar
  53. Knoedler JJ, Boorjian SA, Kim SP, Weight CJ, Thapa P, Tarrell RF, Cheville JC, Frank I. Does partial cystectomy compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy? A matched case-control analysis. J Urol. 2012;188(4):1115–9.PubMedCrossRefGoogle Scholar
  54. Kohjimoto Y, Iba A, Shintani Y, Inagaki T, Uekado Y, Hara I. Impact of patient age on outcome following bladder-preserving treatment for non-muscle-invasive bladder cancer. World J Urol. 2010;28(4):425–30.PubMedCrossRefGoogle Scholar
  55. Koroukian SM, Xu F, Bakaki PM, Diaz-Insua M, Towe TP, Owusu C. Comorbidities, functional limitations, and geriatric syndromes in relation to treatment and survival patterns among elders with colorectal cancer. J Gerontol Ser A Biol Med Sci. 2010;65(3):322–9.CrossRefGoogle Scholar
  56. Levit LA, IoM, Ganz PA, Nass S, Balogh E, Levit L. Delivering high-quality cancer care: charting a new course for a system in crisis. Washington, DC: National Academies Press; 2013.CrossRefGoogle Scholar
  57. Lightfoot AJ, Rosevear HM, O’Donnell MA. Recognition and treatment of BCG failure in bladder cancer. Sci World J. 2011;11:602–13.CrossRefGoogle Scholar
  58. Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, Kaufman DS, Heney NM, Zietman AL. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014;32(34):3801–9.PubMedPubMedCentralCrossRefGoogle Scholar
  59. Messing EM, Madeb R, Feng C, Stephenson L, Gilchrist KW, Young T, Gee J. Grade and stage at presentation do not predict mortality in patients with bladder cancer who survive their disease. J Clin Oncol. 2009;27(15):2443–9.PubMedCrossRefGoogle Scholar
  60. Mohamed N, Diefenbach M, Goltz H, Lee C, Latini D, Kowalkowski M, Philips C, Hassan W, Hall S. Muscle invasive bladder cancer: from diagnosis to survivorship. Adv Urol. 2012;2012:142135.PubMedPubMedCentralCrossRefGoogle Scholar
  61. Mohile SG, Xian Y, Dale W, Fisher SG, Rodin M, Morrow GR, Neugut A, Hall W. Association of a cancer diagnosis with vulnerability and frailty in older Medicare beneficiaries. J Natl Cancer Inst. 2009;101:1206.PubMedPubMedCentralCrossRefGoogle Scholar
  62. Mohile S, Dale W, Hurria A. Geriatric oncology research to improve clinical care. Nat Rev Clin Oncol. 2012;9(10):571–8.PubMedPubMedCentralCrossRefGoogle Scholar
  63. Nielsen ME, Shariat SF, Karakiewicz PI, Lotan Y, Rogers CG, Amiel GE, Bastian PJ, Vazina A, Gupta A, Lerner SP. Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol. 2007;51(3):699–708.PubMedCrossRefGoogle Scholar
  64. Nishijima TF, Muss HB, Shachar SS, Moschos SJ. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis. Cancer Treat Rev. 2016;45:30–7.PubMedCrossRefGoogle Scholar
  65. Noon A, Albertsen P, Thomas F, Rosario D, Catto J. Competing mortality in patients diagnosed with bladder cancer: evidence of undertreatment in the elderly and female patients. Br J Cancer. 2013;108(7):1534–40.PubMedPubMedCentralCrossRefGoogle Scholar
  66. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41(5):582–92.PubMedGoogle Scholar
  67. Nuhn P, May M, Sun M, Fritsche H-M, Brookman-May S, Buchner A, Bolenz C, Moritz R, Herrmann E, Burger M. External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder. Eur Urol. 2012;61(1):58–64.PubMedCrossRefGoogle Scholar
  68. Oddens JR, Sylvester RJ, Brausi MA, Kirkels WJ, van de Beek C, van Andel G, de Reijke TM, Prescott S, Witjes JA, Oosterlinck W. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. Eur Urol. 2014;66(4):694–701.PubMedCrossRefGoogle Scholar
  69. Oddens JR, Sylvester RJ, Brausi MA, Kirkels WJ, Beek C, Andel G, Reijke TM, Prescott S, Alfred Witjes J, Oosterlinck W. Increasing age is not associated with toxicity leading to discontinuation of treatment in patients with urothelial non-muscle-invasive bladder cancer randomised to receive 3 years of maintenance bacille Calmette–Guérin: results from European Organisation for Research and Treatment of Cancer Genito-Urinary Group study 30911. BJU Int. 2016;118:423.PubMedCrossRefGoogle Scholar
  70. Pal SK, Katheria V, Hurria A. Evaluating the older patient with cancer: understanding frailty and the geriatric assessment. CA Cancer J Clin. 2010;60(2):120–32.PubMedCrossRefGoogle Scholar
  71. Palou J, Sylvester RJ, Faba OR, Parada R, Peña JA, Algaba F, Villavicencio H. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Eur Urol. 2012;62(1):118–25.PubMedCrossRefGoogle Scholar
  72. Parkinson JP, Konety BR. Health related quality of life assessments for patients with bladder cancer. J Urol. 2004;172(6):2130–6.PubMedCrossRefGoogle Scholar
  73. Prout GR, Wesley MN, Yancik R, Ries LA, Havlik RJ, Edwards BK. Age and comorbidity impact surgical therapy in older bladder carcinoma patients. Cancer. 2005;104(8):1638–47.PubMedCrossRefGoogle Scholar
  74. Psutka SP, Carrasco A, Schmit GD, Moynagh MR, Boorjian SA, Frank I, Stewart SB, Thapa P, Tarrell RF, Cheville JC. Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer. 2014;120(18):2910–8.PubMedCrossRefGoogle Scholar
  75. Reeve BB, Potosky AL, Smith AW, Han PK, Hays RD, Davis WW, Arora NK, Haffer SC, Clauser SB. Impact of cancer on health-related quality of life of older Americans. J Natl Cancer Inst. 2009;101(12):860–8.PubMedPubMedCentralCrossRefGoogle Scholar
  76. Roaldsen M, Aarsaether E, Knutsen T, Patel HR. Strategies to improve quality of life in bladder cancer patients. Expert Rev Pharmacoecon Outcomes Res. 2014;14(4):537–44.PubMedCrossRefGoogle Scholar
  77. Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 2006;176(6):2414–22.PubMedCrossRefGoogle Scholar
  78. Shariat SF, Milowsky M, Droller MJ. Bladder cancer in the elderly. Urol Oncol. 2009;27:653–67. ElsevierPubMedPubMedCentralCrossRefGoogle Scholar
  79. Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S, Bochner BH. The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int. 2010;105(3):300–8.PubMedCrossRefGoogle Scholar
  80. Shi B, Zhang K, Zhang J, Chen J, Zhang N, Xu Z. Relationship between patient age and superficial transitional cell carcinoma characteristics. Urology. 2008;71(6):1186–90.PubMedCrossRefGoogle Scholar
  81. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.PubMedCrossRefGoogle Scholar
  82. Singer S, Ziegler C, Schwalenberg T, Hinz A, Götze H, Schulte T. Quality of life in patients with muscle invasive and non-muscle invasive bladder cancer. Support Care Cancer. 2013;21(5):1383–93.PubMedCrossRefGoogle Scholar
  83. Solana R, Pawelec G, Tarazona R. Aging and innate immunity. Immunity. 2006;24(5):491–4.PubMedCrossRefGoogle Scholar
  84. Solsona E, Iborra I, Collado A, Rubio-Briones J, Casanova J, Calatrava A. Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. J Urol. 2010;184(2):475–81.PubMedCrossRefGoogle Scholar
  85. Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD, Vogelzang NJ. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol. 2010;11(9):861–70.PubMedCrossRefGoogle Scholar
  86. Spencer BA, McBride RB, Hershman DL, Buono D, Herr HW, Benson MC, Gupta-Mohile S, Neugut AI. Adjuvant intravesical bacillus Calmette-Guérin therapy and survival among elderly patients with non–muscle-invasive bladder cancer. J Oncol Pract. 2013;9(2):92–8.PubMedCrossRefGoogle Scholar
  87. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng A-C, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666–75.PubMedCrossRefGoogle Scholar
  88. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466–77.PubMedCrossRefGoogle Scholar
  89. Thomas F, Rosario DJ, Rubin N, Goepel JR, Abbod MF, Catto JW. The long-term outcome of treated high-risk nonmuscle-invasive bladder cancer. Cancer. 2012;118(22):5525–34.PubMedCrossRefGoogle Scholar
  90. von der Maase H, Hansen S, Roberts J, Dogliotti L, Oliver T, Moore M, Bodrogi I, Albers P, Knuth A, Lippert C. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–77.PubMedCrossRefGoogle Scholar
  91. Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA. 2001;285(21):2750–6.PubMedCrossRefGoogle Scholar
  92. Wildes TM, Ruwe AP, Fournier C, Gao F, Carson KR, Piccirillo JF, Tan B, Colditz GA. Geriatric assessment is associated with completion of chemotherapy, toxicity, and survival in older adults with cancer. J Geriatr Oncol. 2013;4(3):227–34.PubMedPubMedCentralCrossRefGoogle Scholar
  93. Witjes JA, Lebret T, Compérat EM, Cowan NC, De Santis M, Bruins HM, Hernández V, Espinós EL, Dunn J, Rouanne M. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2016.
  94. Yazbek-Hanna M, Whelan P, Jain S. Bladder cancer. Medicine. 2016;44(1):52–5.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of UrologyUniversity HospitalSt. EtienneFrance
  2. 2.Université Jean MonnetSt. EtienneFrance

Section editors and affiliations

  • Etienne Brain
    • 1
  1. 1.Department of Medical Oncology, Institute CurieHôpital René HugueninSaint-CloudFrance

Personalised recommendations